Ropinirole
- Generic Name
- Ropinirole
- Brand Names
- Requip
- Drug Type
- Small Molecule
- Chemical Formula
- C16H24N2O
- CAS Number
- 91374-21-9
- Unique Ingredient Identifier
- 030PYR8953
- Background
Ropinirole, also known as ReQuip, is a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome , . It is manufactured by GlaxoSmithKline Pharmaceuticals. Ropinirole was initially approved in 1997 by the FDA for the management of Parkinson's disease. In 2005, it was the first drug approved in the US for the management of primary ...
- Indication
For the treatment of the signs and symptoms of Parkinson's disease and for the treatment of primary moderate-severe restless legs syndrome .
- Associated Conditions
- Idiopathic Parkinson's Disease, Moderate restless legs syndrome (RLS), Parkinson's Disease (PD), Severe restless legs syndrome (RLS)
- Associated Therapies
- -
Parkinson's Disease Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole
- Conditions
- First Posted Date
- 2007-04-13
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 28
- Registration Number
- NCT00460148
- Locations
- 🇿🇦
GSK Investigational Site, George, Eastern Cape, South Africa
Restless Legs Patient Study On Absorption, Distribution, Metabolism And Excretion Of Ropinirole And The Effect Of Food
- First Posted Date
- 2007-01-09
- Last Posted Date
- 2017-10-13
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 32
- Registration Number
- NCT00419692
- Locations
- 🇿🇦
GSK Investigational Site, George, South Africa
Investigational Parkinson's Disease In Patients Not Well Controlled On L-dopa
- Conditions
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 393
- Registration Number
- NCT00381472
- Locations
- 🇪🇸
GSK Investigational Site, Barcelona, Spain
Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)
- Conditions
- First Posted Date
- 2006-08-23
- Last Posted Date
- 2012-03-07
- Lead Sponsor
- Axxonis Pharma AG
- Target Recruit Count
- 300
- Registration Number
- NCT00367822
- Locations
- 🇩🇪
IMEREM GmbH, Nuremberg, Germany
A Clinical Research Study Testing Ropinirole Treatment for Restless Legs Syndrome
- Conditions
- First Posted Date
- 2006-08-15
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 360
- Registration Number
- NCT00363857
- Locations
- 🇺🇸
GSK Investigational Site, Walla Walla, Washington, United States
The Effects Of Ropinirole On Mood Or Mild Depression In Patients With Moderate To Severe Restless Legs Syndrome
- Conditions
- First Posted Date
- 2006-07-27
- Last Posted Date
- 2012-06-07
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 240
- Registration Number
- NCT00357097
- Locations
- 🇩🇪
GSK Investigational Site, Berlin, Germany
A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar Depression.
- Conditions
- First Posted Date
- 2006-06-09
- Last Posted Date
- 2006-06-09
- Lead Sponsor
- Sheba Medical Center
- Target Recruit Count
- 60
- Registration Number
- NCT00335205
- Locations
- 🇮🇱
Chaim Sheba Medical Center, Dept. of Psychiatry, Tel Hashomer, Israel
🇮🇱Jerusalem Mental Health Center, Jerusalem, Israel
Long-term Study Of Ropinirole In Restless Legs Syndrome
- First Posted Date
- 2006-05-25
- Last Posted Date
- 2017-03-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 404
- Registration Number
- NCT00329602
- Locations
- 🇨ðŸ‡
GSK Investigational Site, Zürich, Switzerland
Ropinirole in the Treatment of Bipolar Depression
- Conditions
- First Posted Date
- 2006-04-17
- Last Posted Date
- 2017-04-18
- Lead Sponsor
- Cambridge Health Alliance
- Target Recruit Count
- 40
- Registration Number
- NCT00314821
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇺🇸Cambridge Health Alliance, Cambridge, Massachusetts, United States
Fibromyalgia Study In Adults
- Conditions
- First Posted Date
- 2005-11-22
- Last Posted Date
- 2016-09-15
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 164
- Registration Number
- NCT00256893
- Locations
- 🇬🇧
GSK Investigational Site, Poole, Dorset, United Kingdom
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.